<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00316628</url>
  </required_header>
  <id_info>
    <org_study_id>V70P3S</org_study_id>
    <secondary_id>Eudract number: 2005-000621-38</secondary_id>
    <nct_id>NCT00316628</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of an Adjuvanted Influenza Vaccine in Subjects Aged 65 Years and Over.</brief_title>
  <official_title>A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, (Adjuvanted With MF59C.1) Influenza Vaccine, Formulation 2005-2006, When Administered to Elderly Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and immunogenicity of a single intramuscular
      (IM) injection of an adjuvanted influenza vaccine in elderly subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CHMP criteria for evaluation of flu vaccines e.g Seroprotection, GMR's and Seroconversion rate at day 21 following vaccination.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with at least one local reaction between Day 0 and Day 3 after vaccine injection.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with at least one systemic reaction between Day 0 and Day 3 after vaccine injection.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with at least one adverse event between Day 0 and the study termination visit (Day 21, window: 20-24).</measure>
  </secondary_outcome>
  <enrollment>50</enrollment>
  <condition>Influenza</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>influenza vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  65 years of age or older and in good health

        Exclusion Criteria:

          -  Any serious disease such as: cancer, autoimmune disease, advanced arteriosclerotic
             disease or complicated diabetes mellitus, chronic obstructive pulmonary disease (COPD)
             that requires oxygen therapy, acute or progressive hepatic disease, acute or
             progressive renal disease, congestive heart failure.

          -  any acute disease or infections requiring systemic antibiotic or antiviral therapy

          -  hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein,
             neomycin or polymyxin or any other component of the vaccine

          -  history of neurological symptoms or signs, or anaphylactic shock following
             administration of any vaccine

          -  known or suspected (or high risk of developing) impairment/alteration of immune
             function within the past 7 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines - Drug Information Services</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>G. D'Annunzio University</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Hygiene and Public Health, ASL Lanciano</name>
      <address>
        <city>Lanciano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2006</study_first_submitted>
  <study_first_submitted_qc>April 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2006</study_first_posted>
  <last_update_submitted>September 13, 2006</last_update_submitted>
  <last_update_submitted_qc>September 13, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2006</last_update_posted>
  <keyword>influenza</keyword>
  <keyword>elderly</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

